Biontech Se Sponsored Adr Stock News

Slower-than-expected data gathering has forced COVID-19 vaccine makers Pfizer (PFE) and BioNTech (BNTX) to delay the delivery of their Omicron-specific shot by several weeks, according…

BERLIN, Feb. 16 (Xinhua) -- The German biotechnology company BioNTech on Wednesday revealed plans to set up a vaccine production facility in Africa. Construction of mRNA production facilities in Africa is planned in Senegal, Rwanda and possibly South Africa, BioNTech said. Together with Pfizer, the company developed one of the first approved COVID-19 vaccines. "Today''s milestone brings us one step closer

BioNTech is developing a turnkey solution to enable mRNA-based vaccine production in modular and scalable sites. The company plans to establish mRNA manufacturing facilities in Africa in partner countries Senegal, Rwanda, and potentially South Africa. Construction of the first facility is expected to start in mid-2022 in a partner country, with the others to follow. A new project in Ghana will support manufacturing with fill-and-finish capacities. The post BioNTech Moves Forward to Promote Scalable Vaccine Production in Africa appeared first on GEN - Genetic Engineering and Biotechnology News .

LONDON: All children aged five to 11 in England will be offered a Covid-19 vaccine, the UK government said Wednesday, following similar announcements in the rest of the UK. The move, coming nearly two months after British regulators approved Pfizer and BioNTech''s shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries. It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective". However, Health Secretary Sajid Javid -- who has responsibility for England only -- said he had now accepted guidance from the Joint Committee on Vaccination and Immunisation, which advises UK health departments, to expand the rollout. "The NHS (National Health Service) will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

BioNTech announced on Wednesday that it plans to create manufacturing facilities in Africa in order to bolster the company''s ability to provide more essential medicines including the COVID-19 vaccine. “Today’s milestone brings us one…

All children aged five to 11 years in the U.K. will be offered Pfizer (PFE)/BIonTech (BNTX) COVID-19 vaccine from April, the government confirmed on Wednesday

German vaccine maker BioNTech, which developed the first widely approved shot against Covid-19 together with Pfizer, unveiled plans on Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent.The modular design presented at a ceremony in Marburg, Germany, consists of shipping containers fitted with the equipment necessary to make the company’s mRNA-based vaccine, save for the final step of putting doses into bottles, a…

Germany''s BioNTech has developed a vaccine factory made from shipping containers that it plans to ship to Africa

Pfizer/BioNTech jab to be offered to younger children as experts decide benefits outweigh risks Coronavirus – latest updates See all our coronavirus coverage Children aged between five and 11 in England will be offered a Covid vaccine, the UK government has confirmed, after similar announcements from Wales and Scotland this week. The move was recommended by the Joint Committee for Vaccination and Immunisation (JCVI), which decided that the vaccination programme should be extended to younger children after lengthy discussions on the benefits and risks. Continue reading…

The first turnkey facility will be shipped to either Senegal or Rwanda in the second half of this year, BioNTech said.

BioNTech SE (NASDAQ: BNTX ), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE ), unveiled plans to establish manufacturing facilities in Africa to boost the availability of much-needed medicines on the continent. The manufacturing solution consists of one drug substance and one formulation module, allowing for mRNA vaccine production in bulk (mRNA manufacturing and formulation). Local partners will take over fill-and-finish. The first turnkey facility will … Full story available on Benzinga.com

The so-called laboratory in a container is being developed by the firm behind the first MRNA vaccine.

BioNTech (BNTX) introduced approach to establish scalable vaccine production in Africa by developing and delivering turnkey mRNA manufacturing facilities based on a container solution.At…

German vaccine maker BioNTech, which developed the first widely approved shot against COVID-19 together with Pfizer, unveiled plans Wednesday to establish manufacturing facilities in Africa that would

BioNTech SE said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company is expecting to deliver the first BioNTainer in the second half, comprising one drug substance and one formulation module. "Each module is built of six ISO sized containers (2.6m x 2.4m x 12m). This allows for mRNA vaccine production in bulk (mRNA manufacturing and formulation), while fill-and-finish will be taken over by local partners. Each BioNTainer is a clean room which BioNTech equips with state-of-the-art manufacturing solutions," the company said in a statement. Two modules will require 800 square meters of space and will have an initial capacity to produce up to 50 million doses of the COVID vaccine BioNTech developed with Pfizer Inc. . The company is expecting to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country and the African Union.